

COMUNICACIÓN DE INFORMACIÓN PRIVILEGIADA

21 de octubre de 2021

En virtud de lo previsto en el artículo 17 del Reglamento (UE) nº 596/2014 sobre abuso de mercado y en el artículo 228 del texto refundido de la Ley del Mercado de Valores, aprobado por el Real Decreto Legislativo 4/2015, de 23 de octubre, y disposiciones concordantes, así como en la Circular 3/2020 de BME MTF Equity, ponemos en su conocimiento:

Se adjunta presentación de resultados de Atrys Health S.A. correspondiente al primer semestre del ejercicio 2021.

Para presentar los resultados se celebrará un “webinar” este jueves 21 de octubre de 2021 a las 12:00 y contará con la presencia por parte de la compañía de Santiago de Torres (Presidente Ejecutivo), Isabel Lozano (CEO) y José María Huch (CFO).

El “webinar” se realizará en colaboración con Rankia.com y contará con un turno de preguntas y respuestas.

Para acceder es preciso ser usuario registrado de Rankia o inscribirse gratuitamente. Se podrá acceder al “webinar” en el siguiente enlace:


<https://www.rankia.com/acciones/atrys-health-atry/webinars/4477-presentacion-resultados-atrys-health-1s2021>

La información comunicada ha sido elaborada bajo exclusiva responsabilidad de Atrys Health, S.A. y sus administradores.

Madrid, 21 de octubre de 2021

Doña Isabel Lozano Fernández

Consejera Delegada



First Semester 2021 Report

October, 2021

Santiago de Torres
Presidente Ejecutivo

Isabel Lozano
CEO

José M^a Huch
CFO

Disclaimer and Cautionary Statements

El presente documento y la conferencia de resultados (incluyendo el turno de preguntas y respuestas) puede contener manifestaciones de futuro e información (de ahora en adelante, “Manifestaciones”) relacionados con ATRYS HEALTH, S.A, o el Grupo ATRYS (de ahora en adelante indistintamente “ATRYS”, la “Compañía” o el “Grupo”). Estas manifestaciones pueden incluir proyecciones y estimaciones financieras con asunciones, declaraciones relativas a planes, objetivos, y expectativas que pueden referirse a diversas materias, entre otras, a la base de clientes y a su evolución, al crecimiento de las distintas líneas de negocio, a la cuota de mercado, a los resultados de la compañía y a otros aspectos relativos a la actividad y situación de la misma.

Las manifestaciones de futuro o previsiones contenidas en este documento pueden ser identificadas, en determinados casos, por la utilización de palabras como “expectativas”, “anticipación”, “propósito”, “creencia” o de un lenguaje similar, o su correspondiente forma negativa, o por la propia naturaleza de la predicción que tienen las cuestiones referidas a estrategias o planes o intenciones. Estas manifestaciones de futuro o previsiones reflejan las opiniones de ATRYS respecto a sucesos futuros, no constituyen, por su propia naturaleza, garantías de un futuro cumplimiento, encontrándose condicionadas por riesgos e incertidumbres que podrían determinar que los desarrollos y resultados finales difieran materialmente de los puestos de manifiesto en estas intenciones, expectativas o previsiones. Entre tales riesgos e incertidumbres están aquellos identificados en los documentos con información más completa registrado por ATRYS ante los diferentes organismos supervisores de los mercados de valores en los que cotiza su acción, y en particular, ante la Comisión Nacional del Mercado de Valores.

Salvo en la medida en que lo requiera la ley aplicable, ATRYS no asume ninguna obligación de actualizar públicamente el resultado de cualquier revisión que pudiera realizar de estas manifestaciones para adaptarla a hechos o circunstancias posteriores a este documento, incluidos, entre otros, cambios en el negocio de la Compañía, en su estrategia de desarrollo de negocio o cualquier posible circunstancia sobrevenida. Este documento puede contener información financiera resumida, non-GAAP o información no auditada. La información contenida en el mismo debe leerse en conjunto y está sujeta a toda la información pública disponible sobre la Compañía, incluyendo, en su caso, otros documentos emitidos por la Compañía que contengan información más completa.

Por último, se hace constar que ni este documento ni nada de lo aquí contenido constituye una oferta de compra, venta o canje, o una solicitud de una oferta de compra, venta o canje de valores, o una recomendación o asesoramiento sobre ningún valor.

This document and the conference-call webcast (including the Q&A session) may contain forward looking statements and information (hereinafter, the “Statements”) relating to ATRYS HEALTH .S.A., or ATRYS Group, (hereinafter indistinctly, “ATRYS”, the “Company” or the “Group”) or otherwise. These Statements may include financial forecasts and estimates based on assumptions or statements regarding plans, objectives and expectations that make reference to different matters, such as the customer base and its evolutions, growth of the different business lines and of the global business, market share, possible acquisitions, divestitures or other transactions, Company’s results and other aspects related to the activity and situations of the Company.

The Statements can be identified, in certain cases, through the use of words such as “forecast”, “expectations”, “anticipation”, “aspiration”, “purpose”, “estimates”, “Plan” or similar expressions or variations of such expressions. These Statements reflect the current views of ATRYS with respect of future events, do not represent, by their own nature, any guarantee of the future fulfilment, and are subject to risks and uncertainties that could cause the final developments and results to materially differ from those expressed or implied by such Statements. These risks and uncertainties include those identified in the documents containing more comprehensive information filed by ATRYS before the different supervisory authorities of the securities markets in which its shares are listed and, in particular, the Mercado Alternativo Bursátil (MaB).

Except as required by applicable law, ATRYS does not assume any obligation to publicly update the Statements to adapt them to events or circumstances taking place after the date hereof, including changes in the Company’s business or business development strategy or any other unexpected circumstance.

This document and the conference-call (including the Q&A session) may contain summarized, non-audited or non-GAAP financial information. The information contained herein and therein should therefore be considered as a whole and in conjunction with all the public information regarding the Company available, including any other documents released by the Company that may contain more detailed information.

Neither this document nor the conference-call (including the Q&A session) nor any of their contents constitute an offer to purchase, sale or exchange any security, a solicitation of any offer to purchase, sale or exchange of any security, or recommendation or advice regarding any security.

“Precision diagnostics, therapeutic innovation and data analytics”


Drivers for value creation for ATRYS shareholders



2021 Speeding up in volume and size as a competitive advantage strategy

- Size is key to establishing strategic agreements with international healthcare groups and becoming a reliable healthcare provider and partner.

	NIIF UE under limited audit review			Profoma
	June 30, 2019	June 30, 2020	June 30, 2021	June 30, 2021
Revenue (M. EUR)	6.1	8.3	41.7	85.1
Adj Ebitda ^(APM) (M.EUR)	1.80	1.78	10.6	22.2
# Employees	71	150	2,121	2,121
Capex + Capex R&D ^(APM) (M.EUR)	2.45	4.27	3.45	3.89
Capex / Revenue (%)	40.2%	51.5%	8.2%	4.5%



Strategic agreements

- Capex and Capex R&D effort are being diluted as the Group is gaining size.

^(APM) See definitions of Alternative Performance Measures on Annex I

⁽¹⁾ Proforma = Includes full first semester 2021 impact of the acquisitions of Lenitudes SGPS, Radio Onkologie Amsler and ASPY Global Services S.A. Non audited information.

Segmented Business Areas:




- Pathology & Genetic diagnostic.
- Advanced radiotherapy treatments.
- Telemedicine.
- Smart Data.

- Health surveillance.
- Prevention services and occupational risks.
- Training services for employees in occupational safety.


- Compliance services provided to companies to adapt processes and protocols for compliance with Personal Data Protection Laws and other regulations.



Radioteraphy Linacs Medical events Lab. test per year Oncology treatments per year




Delegations Employees covered Medical examinations per year



Clients porfolio

2018-2021 acquisitions by segmented divisions:



ASPY

- Aspy centers providing Covid Test with the support of Atrys laboratories.
- Introduction of online medical specialised services in Aspy portfolio: Teleophthalmology, Teledermatology,
- The combination of Atrys - Aspy increases the suitability to participate in private tenders: Telemedicine, Dermatological tests, Ophthalmological and Cardiology examinations offered through the large Aspy network of healthcare centers.
- Executive medicine units and comprehensive health medical centers under implementation in Barcelona and Madrid, including Atrys' specialized health services.
- Network of extraction centers to collect samples to be tested at Atrys and partners laboratories.
- Virtual healthcare project for companies: introduction of Atrys telemedicine platform for Aspy's clients wishing to offer social benefits to their employees.
- R&D projects: first grant application submitted to carry out an AI project "*Virtual specialist for the assessment of medical skills*", allowing occupational medicine specialists to devote their time to higher value-added tasks.

Accelerated growth through strategic agreements with other healthcare groups in 2021



Champalimaud
Foundation

Champalimaud Foundation (“CF”) is a private Portuguese scientific research institution whose mission is to drive advanced biomedical research for the benefit of patients and to provide excellent clinical oncology care.

CF operates a state-of-the-art research and therapy center in Lisbon, Portugal, designated “**The Champalimaud Center for the Unknown**”, recognized as one of the leading international centres for cancer prevention, diagnosis and treatment.

Atrys and CF will collaborate with the aim to implement, develop and ensure wider access to high quality medical, diagnostic and therapeutic procedures and to improve the quality of the healthcare services provided to oncological patients.

- Perform state-of-the-art diagnostic and cancer treatments with non-invasive approaches, using advanced imaging, high-precision radiotherapy, advanced systemic therapy, AI, telemedicine and other novel technologies and processes.
- Implement clinical protocols utilized by CF at the facilities owned and managed by Atrys. The agreement will allow the optimization of patient care in each of these centers, achieving better response times and avoiding unnecessary travel.
- The Atrys and CF network will have common international tumor committees offering a multidisciplinary vision and the best alternatives to patients.
- Collaborate in R&D projects to improve cancer treatment applying genetics, molecular pathology and AI.
- CF will provide Atrys access to its know-how, methodologies and processes and intellectual property. The Atrys centers in Portugal, Spain and Switzerland will operate under the dual brand Atrys-CF.

Size speed up strategic agreements with other healthcare groups in 2021



- Sanitas and Atrys will open a new site of the Institute of Advanced Oncology (IOA), a comprehensive care model for people with cancer that has obtained very good clinical results and high patients' satisfaction in its first year of activity in Barcelona.
- The IOA Madrid will offer a comprehensive response to the needs of cancer patients with all available diagnostic and treatment resources, including radiotherapy state-of-the-art technology.
- This new center will be located next to the Hospital Universitario La Moraleja, in the north of Madrid. It will serve the oncology units of the three hospitals that Sanitas has in Madrid: La Moraleja, La Zarzuela and Virgen del Mar, and it will be an open center for all those patients who require high precision cancer treatments.



- Atrys and Lusiadas Saúde Group, one of the main health players in Portugal, part of the global healthcare group United Health, entered into an agreement for the installation of a radiotherapy unit at CLISA, (San Antonio Clinic at Lisbon), a hospital owned by Lusiadas, that will be managed by Atrys.
- With this agreement, Atrys begins its activity in the Portuguese capital and continues its consolidation in Portugal, where it already has a strong presence in the field of cancer treatment, diagnostic imaging, nuclear medicine and genetics.
- The alliance strengthens Atrys in the field of radiation oncology therapy in Europe and enhance its strategy of creating a reference network of high-precision radiotherapy centers.

First semester 2021 Report

Income Statement 1st semester 2021

(thousands EUR)	NIIF UE under limited audit review			Proforma ⁽¹⁾
	6m ended			6m ended
	June 30, 2020	June 30, 2021	Var (%) 2020/21	June 30, 2021
Turnover	8.344	41.705	400%	85.092
Gross Margin ^(APM)	6.086	31.694	421%	73.514
<i>% gross margin on turnover</i>	72,9%	76,0%	--	86,4%
EBITDA ^(APM)	1.421	7.571	433%	17.850
Non recurrent expenses	363	3.059	743%	4.354
Adjusted EBITDA ^(APM)	1.784	10.630	496%	22.204
<i>% adjusted EBITDA on turnover</i>	21,4%	25,5%	--	26,1%
Net Profit	(1.086)	(3.313)	205%	(3.891)
Capex R&D ^(APM)	891	1.348	51%	1.368
Capex ^(APM)	3.382	2.104	-38%	2.531
Operating Cash Flow ^(APM)	(2.852)	4.120	--	13.951
Adjusted Operating Cash Flow ^(APM)	(2.489)	7.178	--	18.305


Data on proforma basis and at constant perimeter

- **Turnover:** increased +9,2% YoY despite a challenging environment in Europe and Latin America in the first quarter of 2021 due to the health crisis caused by COVID19.
- **Adjusted EBITDA:** increased +35% thanks to the positive impact of cost synergies executed from 2020 acquisitions and the dilution of overhead OPEX expenses as the Group increases its size and improves its operating leverage.
- **Net Profit:** negative of (3.89M) EUR impacted by one-off financial expenses and non recurrent OPEX expenses.

^(APM) See definitions of Alternative Performance Measures on Annex I


⁽¹⁾ Proforma = Includes full first semester 2021 impact of the acquisitions of Lenitudes SGPS, Radio Onkologie Amsler and ASPY Global Services S.A. Non audited information.

1st Semester 2021 Proforma result before taxes impacted by one-off expenses



Proforma = Includes full first semester 2021 impact of the acquisitions of Lenitudes SGPS, Radio Onkologie Amsler and ASPY Global Services S.A. Non audited information.

1st Semester 2021 Proforma Revenue by geographic area



(thousands EUR)


Spain
Portugal
Switzerland
LatAm
Total Revenue

Proforma ⁽¹⁾ 6m ended		
June 30, 2020	June 30, 2021	Var (%) 2020/21
60.026	64.527	7,5%
5.566	6.430	15,5%
2.769	2.513	-9,2%
9.584	11.622	21,3%
77.945	85.092	9,2%

- **Spain & Portugal:** All business areas are quickly recovering from COVID19 crisis in 1st semester 2021. Except in radiotherapy, where we are receiving patients for treatment in later cancer stages due to limited access to diagnostic support during the COVID19 crisis.
- **Switzerland:** Activity is focused exclusively on radiotherapy treatments, where we are receiving patients for treatment in later cancer stages due to limited access to diagnostic support during the COVID19 crisis.
- **LatAm:** Strong recovery of the activity of the tele-diagnosis business area in 1st semester 2021.

⁽¹⁾ Proforma = Includes full first semester 2021 impact of the acquisitions of Lenitudes SGPS, Radio Onkologie Amsler and ASPY Global Services S.A. Non audited information.

1st Semester 2021 Proforma Revenue by business segment



(thousands EUR)

Precision Medicine
Prevention Medicine
Compliance Services
Total Revenue


Proforma ⁽¹⁾ 6m ended		
June 30, 2020	June 30, 2021	Var (%) 2020/21
28.730	32.129	11,8%
37.929	40.154	5,9%
11.286	12.809	13,5%
77.945	85.092	9,2%

- **Precision Medicine:** All business areas are recovering quickly from COVID19 crisis in 1st semester 2021. Except in radiotherapy, where we are receiving patients for treatment in later cancer stages due to limited access to diagnostic support during COVID19 crisis.
- **Prevention Medicine:** Strong 1st semester revenue increase despite the impact of the COVID19 crisis on Spanish SMEs.
- **Compliance Services:** Strong 1st semester revenue increase despite the impact of the COVID19 crisis on Spanish SMEs.

⁽¹⁾ Proforma = Includes full first semester 2021 impact of the acquisitions of Lenitudes SGPS, Radio Onkologie Amsler and ASPY Global Services S.A. Non audited information.

Thousand EUR	6m ended June 30, 2021
a) Gross Debt ⁽¹⁾	159.193
Debt with Banks	86.836
Debt with public entities	7.508
Other financial debt	4.357
Bond Programme and Convertible Bond	60.492
b) Cash	20.744
Cash	18.095
Restricted cash linked to debt	2.648
c) Net Financial Debt ⁽¹⁾	138.450

Debt maturity schedule:
Millions EUR.



- In October 2021 a real estate asset was sold in Portugal for €17,8M. The proceeds obtained have been used to cancel and repay a €18M Bank loan.
- €10M Convertible Bond at strike price of €6.0 per share could be converted into equity in 2022.
- Debt refinance expected to be completed in November 2021, reducing debt cost and gaining maturity time.


¹ See definitions in Annex I

First semester 2021 Report


ATRYs share



Atrys market cap evolution BME Growth (€M)



Share turnover (€M)



Since its IPO in June 2016 in BME growth, ATRYS share has experienced a 525.0% increase in market value versus a 3.8% increase of the IBEX-35 index for the same period.

The IRR for ATRYS shareholders, from June 2016 to October 2021, was +44.3%.

¹ Market cap at October 06, 2021

² 1S 2021 share turnover at October 06, 2021

2021-2022 strategic goals

- Expand Company's footprint in Europe through acquisitions.
- Accelerate diagnostic automation by incorporating AI tools in order to reduce costs and improve diagnostic quality.
- Enhance our data analytics through Smart/Big Data.
- Introduce new services in Europe (tele-consultation, monitoring of chronic patients).
- Listing in the Spanish main equity market (“*Mercado Continuo*”) for improvement in liquidity, entry of international investment funds and exchange-traded fund (ETFs).
- Balance sheet structure and hidden assets optimization.
- Continue to create value for shareholders through organic growth, implementation of synergies and inorganic growth.
- Speeding up strategic agreements with healthcare groups.




Image of cancer centers of ROAG in Basel, Switzerland



Q&A



APPENDIX

Image ICM Genetic Centre in Lugo. Spain.

Terms and definitions

Gross margin:

Is the net amount of the turnover minus the supplies. The Gross Margin is considered by the Company as a measure of the performance of its activity, since it provides information on net sales, subtracting the cost incurred to achieve said sales.

Gross margin on turnover:

Corresponds to the gross margin divided by the turnover amount.

EBITDA:

Sum of the items "Gross margin", "Work carried out by the group for its assets", "Other operating income", "Allocation of subsidies for non-financial fixed assets and others" and "operating expenses".

Adjusted EBITDA:

Corresponds to EBITDA for the year excluding non-recurring expenses. It means non-recurring "One Shot" expenses that come from operations in capital markets and derived from M&A activity, compensation for layoffs of personnel in job positions that are amortized, or the impact on operating results derived from incentive plans for employees that can be remunerated with Group shares, as well as extraordinary provisions of a non-recurring nature and any other operational and optimization adjustments that imply an initial and punctual expense that is compensated during the following 12 months. As well as the amount of incentive plans for the Group's management team recognized in an expense account that do not involve a cash outflow.

Adjusted EBITDA on turnover:

Corresponds to the Adjusted EBITDA divided by the turnover amount.

Operating cash flow:

EBITDA of the period minus the CAPEX and CAPEX R&D.

Adjusted operating cash flow:

Means Adjusted EBITDA for the period minus CAPEX and CAPEX R&D.

Gross Financial Debt (GFD):

Sum of the following items: "Debts with credit institutions", "Debts with public entities", "MARF bond program" and "Convertible bond" of the Consolidated Annual Accounts.

Net Financial Debt (NFD):

Gross Financial Debt (GFD), minus the headings "Cash and other equivalent liquid assets", "Guarantees and deposits" and "deposits" of the Group's Consolidated Annual Accounts that comply with the condition that they be immediate liquid assets or are intrinsically linked as collateral for any of the items of Gross Financial Debt.

Capex:

Any expense incurred in relation to the productive capacity and profitability of the Group's assets and reflected in the Consolidated Annual Accounts in the statement of cash flows from investing activities, excluding company acquisitions (Business Unit).

Funds used by the Group to buy, improve, maintain or develop its tangible or intangible assets, such as buildings, machinery, technology or equipment.

R&D Capex:

Investment in assets related to the development of the Group's R&D activity. It is the sum of additions to Development and additions to Industrial Property in the Group's Intangible Assets.

Terms and definitions

Covenant:

Agreement between the Group and its lenders to keep certain limitations to the Group's indebtedness.

COVID19:

The novel SARS-CoV-2 coronavirus is a new type of coronavirus that was first detected in December 2019 in Wuhan City, Hubei Province, China.

Group's Auditor:

It refers to KPMG Auditores S.L.

Net assets / Shareholders equity:

As of 31th December of each year, it means the amount of the Caption Net Assets / Shareholders equity included in the Audited Consolidated Accounts. For the purposes of the covenant's calculation, the Treasury Shares amount will be excluded from the Net Equity figure.

IOA:

Instituto de Oncología Avanzada

Thank you